Tao and colleagues found that EZH2 inhibitors could reactivate TET1 expression in basal-like breast cancer cell lines, indicating that TET1 gene might be epigenetically repressed by H3K27me3 in basal-like breast cancer [31]. This evidence concerns the gene EZH2 and breast carcinoma.